Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-12-12
2009-12-08
Landau, Sharmila Gollamudi (Department: 1611)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254010, C514S266200, C514S314000, C514S326000, C514S367000, C514S385000, C514S422000, C514S423000, C544S141000, C544S285000, C544S372000, C546S176000, C546S208000, C548S178000, C548S306100, C548S518000, C548S525000, C548S531000
Reexamination Certificate
active
07629340
ABSTRACT:
Disclosed are compounds having Formula (I) and the compositions and methods relating to these compounds, for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R2, m, R, V, W, T, Z, R1, Y, and p are disclosed herein.
REFERENCES:
patent: 4107288 (1978-08-01), Oppenheim et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5607915 (1997-03-01), Patton
patent: 5738985 (1998-04-01), Miles et al.
patent: 2006/0276511 (2006-12-01), Serrano-Wu et al.
patent: 2007/0265265 (2007-11-01), Schmitz et al.
patent: WO 03/045912 (2003-06-01), None
patent: WO 2004/014313 (2004-02-01), None
patent: WO 2004/014852 (2004-02-01), None
Njoroge et al. “Challenges in Modern Drug Discover: A Case Study of Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus Infection” Acc. Chem. Res. 2008, 41(1) 50-59.
Mitsch et al. (“Non-thiol Farnesyltransferase Inhibitors: FTase-Inhibition and Cellular Activity of Benzophenone-based Bisubstrate Analogue Farnesyltransferase Inhibitors” Archiv der Pharmazie, 2003, 336, 242-250.).
Beaulieu, P.L. et al. “Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections.”Curr Opin Investig Drugs5(8):838-50 (2004).
Ferrari, E. et al. “Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed inEscherichia coli.” J Virol73(2):1649-54 (1999).
Fried, M.W. et al. “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.”N. Engl J Med347(13):975-82 (2002).
Griffith et al. “HCV Anti-viral Agents.”Ann Rep Med Chem39:223-37 (2004).
Hoofnagle, J.H. “Hepatitis C: the clinical spectrum of disease.”Hepatology26(3 Suppl 1):15S-205S (1997).
Horsmans, Y. et al. “Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.”Hepatology42(3):724-31 (2005).
Ishii, K. et al. “Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding.”Hepatology29(4):1227-35 (1999).
Lohmann, V. et al. “Selective stimulation of hepatitis C virus and pestivirus NS5B RNA polymerase activity by GTP.”J Biol Chem274(16):10807-15 (1999).
Moriishi, K. et al. “Mechanisms of hepatitis C virus infection.”Antivir Chem Chemother14(6):285-97 (2003).
Ni, Z.J. et al. “Progress and development of small molecule HCV antivirals.”Curr Opin Drug Discov Develop7(4):446-59 (2004).
Saunders, J.O. et al. “Inosine Monophosphate Dehydrogenase: Consideration of Structure, Kinetics and Therapeutic Potential.”Ann Rep Med Chem25:201-10 (2000).
Szabo, E. et al. “Viral hepatitis: new data on hepatitis C infection.”Pathol Oncol Res9(4):215-21 (2003).
Thomson, B.J. et al. “Hepatitis C virus infection.”Clin Microbiol Infect11(2):86-94 (2005).
Watashi, K. et al. “Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.”Mol Cell19(1):111-22 (2005).
Yamashita, T. et al. “RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region.”J Biol Chem273(25):15479-86 (1998).
Krieger et al. “Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.”J Virol. May 2001; 75(10):4614-24.
Denmark et al. “Synthesis of Phosphoramides for the Lewis Base-Catalyzed Allylation and Aldo Addition Reactions.”Journal of Organic Chemistry, vol. 64, 1999, pp. 1958-1967.
Hadfield et al. “An Unexpected Mitsunobu Reaction. A Direct Route to the 2,5-Diaza-Bicyclo2.2.1Heptan-3-One Skeleton As a Gamma-Lactam Mimic of Beta-Lactam Antibiotics.”Journal of the Chemical Society, Perkin Transactions 1, Chemical Society. Letchworth, GB, No. 4, 1997, pp. 503-509.
Mori et al. “New Synthesis of Pyrrolo-1, 4-Benzodiazepines by Utilizing Palladium-Catalyzed Carbonylation.”Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, Tokyo, JP, vol. 32, No. 10, Oct. 1984, pp. 3840-3847.
Rhyoo et al. “Use of Amino Amides Derived From Proline As Chiral Ligands in the Ruthenium(II)-Catalyzed Transfer Hydrogenation Reaction of Ketones.”Tetrahedron Letters, Elsevier, Amsterdam, NL, vol. 42, No. 30, Jul. 23, 2001, pp. 5045-5048.
Abadi Ali Dehghani Mohammad
Griffith Ronald Conrad
Leivers Martin Robert
Roberts Christopher Don
Schmitz Franz Ulrich
Brink Robert H.
Klinkel Kortney L
Landau Sharmila Gollamudi
SmithKline Beecham Corporation
LandOfFree
N-(6-membered aromatic ring)-amido anti-viral compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-(6-membered aromatic ring)-amido anti-viral compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(6-membered aromatic ring)-amido anti-viral compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4078098